PT-日记文章Au -Loebinger，Michael R. Au -Polverino，Eva au -Chalmers，James D. au -Tiddens，Harm A.W.M.Au -Goossens，Herman au -Tunney，Michael Au -Ringshausen，Felix C. Au -Hill，Adam T. au -au -Pathan，Rashidkhan au -angyalosi -angyalosi，Gerhild au -blasi -blasi -blasi，Francesco au-Charles S. Ed-，Ti- Tobi Podhaler在 pseudomonas aeruginosa中的功效和安全性 - 感染受感染的支气管扩张患者：IBEST研究AID -10.1183/13993003.01451-20201451-2020 DP-2021 DP -2021 JAN 01 TA-欧洲呼吸期刊PG-2001451 VI -57 IP -1 4099 -http：//www.qdcxjkg.com/content/57/1/1/2001451.short 4100 -http：//www.qdcxjkg.com/content/57/1/1/2001451.full-UR呼吸J2021 1月1日；57 AB-该研究的目的是确定在铜绿假单胞菌痰密度上安全且耐受良好的剂量和耐植物吸入粉（TIP）的疗效。慢性铜绿假单胞菌感染≥18岁的支气管扩张患者。患者被随机分别为1：1：1，以分别为A：每天三个尖端胶囊（84 mg）；队列B：每天五个胶囊（140 mg）或队列C：每天两次（224 mg）四胶囊。在每个队列中，将患者进一步随机2：2：1，要么连续尖端，分别循环（交替的28天和安慰剂）或安慰剂16周，然后进行了8周的跟踪。 to cohorts A (n=34), B (n=36) and C (n=37). All three TIP doses significantly reduced the P. aeruginosa sputum density from baseline to day 29 versus placebo in a dose-dependent manner (p≤0.0001, each). A smaller proportion of patients in the continuous-TIP (34.1%) and cyclical-TIP (35.7%) groups experienced pulmonary exacerbations versus placebo (47.6%) and also required fewer anti-pseudomonal antibiotics (38.6% on continuous TIP and 42.9% on cyclical TIP) versus placebo (57.1%) although not statistically significant. Pulmonary exacerbation of bronchiectasis was the most frequent (37.4%) adverse event. Overall, TIP was well tolerated, however, 23.4% of the patients discontinued the study drug due to adverse events.Continuous- and cyclical-TIP regimens with all three doses were safe and effective in reducing the P. aeruginosa sputum density in patients with bronchiectasis and chronic P. aeruginosa infection.Inhaled dry powder tobramycin (TOBI Podhaler) significantly reduced Pseudomonas aeruginosa sputum density and was well tolerated in patients with bronchiectasis https://bit.ly/3hsRQw9